Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Published byCatherine Manning Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection."— Presentation transcript:

1 Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs
Figure 2 | Modelling the effect of HCV treatment on reinfection in people who inject drugs. Mathematical modelling was used to evaluate the effect of increased treatment on HCV reinfection among PWID in Australia. Each line represents the expected number of individuals with HCV reinfection (secondary infections, left axis) in each year, based on a given annual HCV treatment scenario. The coloured lines represent the annual proportion of PWID treated per year. Image and data presented80 courtesy of H. Razavi. Image and data presented courtesy of H. Razavi Grebely, J. et al. (2017) Direct-acting antiviral agents for HCV infection affecting people who inject drugs Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection."

Similar presentations

Prevention, Treatment and Care of Hepatitis C among People Who Inject Drugs Jason Grebely, PhD Senior Lecturer Viral Hepatitis Clinical Research Program.

Prevention, Treatment and Care of Hepatitis C among People Who Inject Drugs Jason Grebely, PhD Senior Lecturer Viral Hepatitis Clinical Research Program.
Hepatitis C treatment as prevention: Could it work?

Hepatitis C treatment as prevention: Could it work?
Lesson 4: Preventing HCV Reinfection

Lesson 4: Preventing HCV Reinfection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Patients cured of HCV infection

Figure 1 Patients cured of HCV infection
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Global epidemiology of common Clostridium difficile ribotypes

Figure 2 Global epidemiology of common Clostridium difficile ribotypes
Figure 2 The microbiome–gut–brain axis

Figure 2 The microbiome–gut–brain axis
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Similar presentations

Ads by Google